Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset ...

Merck said it expected sales of $64.1 billion to $65.5 billion in 2025 and adjusted earnings of $8.88 to $9.03 a share. Both forecasts came in below the average analyst expectation for revenue of ...

Truist Securities expressed confidence in its latest note that Merck will be able to navigate the upcoming Gardasil headwinds ...

Its shares are up by 11.6 ... day 1.60% higher. Cramer was exasperated: “Is Disney somehow a winner? I mean you see these things that are just up and you want to say, are you kidding?” Merck ...

Reports Q4 revenue $15.6B, consensus $15.51B. “We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including ...

Nexon has shared early update 1.2.6 patch notes for The First Descendant, and they outline some new features coming very soon.

Merck swung to a fourth-quarter profit as sales grew and even exceeded Wall Street's estimates, boosted in part by the performance of top asset Keytruda. The drug company logged net income of $3.74 ...

Merck has traditionally eschewed large-scale M&A, but has been warming to the concept in recent years, with deals including its $11.5 billion takeover of Acceleron last year and its $2.75 billion ...

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.